Your browser doesn't support javascript.
loading
A risk calculator predicting recurrence in lymph node metastatic penile cancer.
Bandini, Marco; Spiess, Philippe E; Pederzoli, Filippo; Marandino, Laura; Brouwer, Oscar R; Albersen, Maarten; Roussel, Eduard; de Vries, Hielke M; Chipollini, Juan; Zhu, Yao; Ye, Ding-Wei; Ornellas, Antonio A; Catanzaro, Mario; Hakenberg, Oliver W; Heidenreich, Axel; Haidl, Friederike; Watkin, Nick; Ager, Michael; Ahmed, Mohamed E; Karnes, Jeffrey R; Briganti, Alberto; Salvioni, Roberto; Montorsi, Francesco; Azizi, Mounsif; Necchi, Andrea.
Afiliação
  • Bandini M; Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
  • Spiess PE; Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Pederzoli F; Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
  • Marandino L; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Brouwer OR; The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Albersen M; University Hospitals Leuven, Leuven, Belgium.
  • Roussel E; University Hospitals Leuven, Leuven, Belgium.
  • de Vries HM; The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Chipollini J; Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Zhu Y; Fudan University Shanghai Cancer Center, Shanghai, China.
  • Ye DW; Fudan University Shanghai Cancer Center, Shanghai, China.
  • Ornellas AA; Hospital Mário Kröeff and Brazilian Cancer Institute, Rio de Janeiro, Brazil.
  • Catanzaro M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Hakenberg OW; University Hospital Rostock, Rostock, Germany.
  • Heidenreich A; Universitätsklinikum Köln, Köln, Germany.
  • Haidl F; Universitätsklinikum Köln, Köln, Germany.
  • Watkin N; St. George's University Hospitals, NHS Foundation Trust, London, UK.
  • Ager M; St. George's University Hospitals, NHS Foundation Trust, London, UK.
  • Ahmed ME; Department of Urology, Mayo Clinic, Rochester, MN, USA.
  • Karnes JR; Department of Urology, Mayo Clinic, Rochester, MN, USA.
  • Briganti A; Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
  • Salvioni R; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Montorsi F; Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
  • Azizi M; Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Necchi A; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
BJU Int ; 126(5): 577-585, 2020 11.
Article em En | MEDLINE | ID: mdl-32662205
ABSTRACT

OBJECTIVES:

To develop and externally validate a risk calculator for prediction of any cancer recurrence in patients with penile squamous cell carcinoma (pSCC) and inguinal lymph node metastases (ILNM), as to date no validated prognostic tool is available for patients with pSCC and ILNM. PATIENTS AND

METHODS:

The development cohort included 234 patients from seven referral centres. The external validation cohort included 273 patients from two additional referral centres. Cox regression identified predictors of any recurrence, which were used to develop a risk calculator. The risk-calculator grouped the development and the validation cohorts according to the individual risk of any recurrence at 24 months (24m-R). Adjuvant treatment effects were tested on overall survival (OS) according to the derived tertiles, within the development and validation cohorts.

RESULTS:

Positive surgical margins, pN3 , and ILNM ratio were associated with higher recurrence rate. The 2-year OS rates were lower for patients with high (>37%) and intermediate (19-37%) compared to low (<19%) 24m-R risk of recurrence, for both the development (43% and 58% vs 83%, P < 0.001) and validation cohort (44% and 50% vs 85%, P < 0.001). Results were confirmed in the subgroup of patients who did not receive adjuvant treatment (P < 0.001), but not in patients who did receive adjuvant treatments in both the development and validation cohorts (P > 0.1).

CONCLUSION:

Adjuvant treatment planning is crucial in patients with pSCC with ILNM, where only weak evidence is available. The current tool proved to successfully stratify patients according to their individual risk, potentially allowing better tailoring of adjuvant treatments.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Penianas / Metástase Linfática / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: BJU Int Assunto da revista: UROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Penianas / Metástase Linfática / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: BJU Int Assunto da revista: UROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália